WuXi teams up with Gilead; PharPoint expands its HQ;

> WuXi PharmaTech ($WX) signed a deal to work with Gilead Sciences ($GILD) on R&D in its native China. News

> CRO PharPoint Research expanded its North Carolina headquarters to account for "stable growth of new employees," the company said. More

Suggested Articles

Data firm Syapse has begun working with the FDA to help bring real-world evidence to bear on the agency’s decisions to approve cancer drugs.

The People-Centered Research Foundation tapped Datavant to de-identify real-world data across its national clinical research network.

Boehringer Ingelheim and MD Anderson Cancer Center have joined forces to create a “virtual” R&D hub so the pair can work on cancer drugs.